LUTATHERA Drug Patent Profile

Which patents cover Lutathera, and when can generic versions of Lutathera launch?

Lutathera is a drug marketed by Aaa Usa Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-three patent family members in twenty-five countries.

The generic ingredient in LUTATHERA is lutetium lu 177 dotatate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu 177 dotatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lutathera

Lutathera was eligible for patent challenges on January 26, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 25, 2039. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUTATHERA

International Patents:	93
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	46
Drug Prices:	Drug price information for LUTATHERA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUTATHERA
What excipients (inactive ingredients) are in LUTATHERA?	LUTATHERA excipients list
DailyMed Link:	LUTATHERA at DailyMed

See drug prices for LUTATHERA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUTATHERA

Constraining patent/regulatory exclusivity:

10,596,278*PED

NDA:

208700

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUTATHERA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Grenoble	PHASE3
Fundacin de investigacin HM	PHASE2
Imperial College London	PHASE2

See all LUTATHERA clinical trials

Paragraph IV (Patent) Challenges for LUTATHERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUTATHERA	Injection	lutetium lu 177 dotatate	10 mCi/mL	208700	1	2023-11-13

US Patents and Regulatory Information for LUTATHERA

LUTATHERA is protected by nine US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,596,278.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes	12,415,003*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes	12,161,732*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes	12,491,272*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes

International Patents for LUTATHERA

When does loss-of-exclusivity occur for LUTATHERA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Denmark

European Patent Office

Finland

Germany

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUTATHERA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4545100
Japan	2022502505
China	120860272
Portugal	4545100

Supplementary Protection Certificates for LUTATHERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	C04095130/01	Switzerland		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTID TETRAXETAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68684 24.02.2023
4095130	CA 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	2490022-7	Sweden		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	202440024	Slovenia		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF NATIONAL AUTHORISATION: 20221209; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Lutathera: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Lutathera (lutetium Lu 177 dotatate) has established a significant market position in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug, developed by Novartis, achieved U.S. Food and Drug Administration (FDA) approval in 2018 and European Medicines Agency (EMA) approval in 2017. Its mechanism of action involves targeted delivery of radiation to tumor cells expressing somatostatin receptors, offering a therapeutic option for patients with advanced disease.

What are the Key Market Drivers for Lutathera?

The market for Lutathera is primarily driven by the increasing incidence and prevalence of GEP-NETs, coupled with the drug's demonstrated efficacy in improving progression-free survival (PFS) and overall survival (OS) in clinical trials. The lack of comparable targeted radioligand therapies in this specific indication further solidifies its market position.

Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

• Incidence: GEP-NETs are considered rare cancers, but their incidence is rising globally. In the United States, the estimated incidence rate is approximately 1.5 to 2.5 cases per 100,000 population annually. (Source: National Cancer Institute)
• Prevalence: The number of individuals living with GEP-NETs is also increasing due to improved diagnostics and longer patient survival. This growing patient population represents a sustained demand for effective treatments.
• Tumor Subtypes: Lutathera is indicated for somatostatin receptor-positive GEP-NETs, which encompass a significant proportion of these tumors.

Clinical Efficacy and Differentiation

• Progression-Free Survival (PFS): The pivotal NETTER-1 trial demonstrated a significant improvement in PFS for patients treated with Lutathera compared to high-dose octreotide. Median PFS was 28.4 months in the Lutathera arm versus 8.5 months in the octreotide arm, representing a 79% reduction in the risk of progression or death. (Source: NETTER-1 Trial Publication)
• Overall Survival (OS): The same trial showed a notable improvement in OS, with median OS not yet reached in the Lutathera arm versus 22.8 months in the octreotide arm. This translated to a 51% reduction in the risk of death. (Source: NETTER-1 Trial Publication)
• Targeted Therapy: Lutathera's mechanism of delivering targeted radiation to tumor cells expressing somatostatin receptors differentiates it from systemic chemotherapy or less targeted therapies, offering a more precise treatment approach.

Regulatory Landscape and Market Access

• FDA Approval: Approved in the U.S. in January 2018 for adults with somatostatin receptor-positive GEP-NETs.
• EMA Approval: Approved in Europe in September 2017.
• Reimbursement: Market access and reimbursement are crucial. While initially facing challenges, favorable pricing and established clinical value have facilitated broader adoption in key markets.

What is Lutathera's Current Market Performance?

Novartis reported net sales for Lutathera in the range of USD $500 million to $600 million annually in recent years. These figures reflect increasing adoption and market penetration.

Sales Figures and Growth Trends

• 2022 Net Sales: Approximately $570 million (Source: Novartis Annual Report 2022)
• 2023 Net Sales: Anticipated to show continued growth, driven by expanding indications and geographical reach. (Source: Analyst reports, company guidance)
• Growth Drivers: Increased diagnosis rates, expanded indications (including pediatric use in some regions), and wider physician adoption contribute to sales growth.

Geographic Market Penetration

• North America: The largest market, driven by high healthcare spending and established reimbursement frameworks.
• Europe: Significant market presence with established regulatory approvals and healthcare systems supporting its use.
• Asia-Pacific: Emerging market with growing potential as awareness and access improve.

What are the Key Challenges and Risks for Lutathera?

Despite its strong market position, Lutathera faces several challenges, including competition, manufacturing complexities, and the high cost of treatment.

Competitive Landscape

• Emerging Radioligand Therapies: The success of Lutathera has spurred development of other radioligand therapies targeting different receptors or utilizing different isotopes. These could potentially compete for patient populations or offer alternative treatment pathways. Examples include:
  • 177Lu-Edotreotide (Talakit®): Under development, targeting somatostatin receptors.
  • Other Isotopes and Ligands: Ongoing research into novel combinations for GEP-NETs and other neuroendocrine tumors.
• Other Treatment Modalities: Traditional treatments like surgery, chemotherapy, and somatostatin analogs remain options for certain patient groups or disease stages.

Manufacturing and Supply Chain Complexities

• Radiopharmaceutical Production: The production of radiopharmaceuticals like Lutathera is complex, requiring specialized facilities and strict quality control.
  • Isotope Availability: Reliance on specific radioactive isotopes can create supply chain vulnerabilities.
  • Cold Chain Management: Maintaining the integrity of radioactive materials during transport is critical.
• Scalability: Scaling up manufacturing to meet growing demand can be a significant challenge.

Cost and Reimbursement Hurdles

• High Treatment Cost: Lutathera is a high-cost therapy, which can present a barrier to access, particularly in healthcare systems with budget constraints. A single cycle of treatment can cost tens of thousands of dollars.
• Reimbursement Approval: Securing and maintaining favorable reimbursement status from various payers is an ongoing process. Delays or denials can significantly impact market uptake.

Potential for Side Effects and Toxicity

• Renal Toxicity: A known side effect that requires careful patient selection and monitoring.
• Myelosuppression: Effects on blood cell counts require management.
• Other Adverse Events: Nausea, vomiting, and fatigue are common.

What is the Future Financial Trajectory for Lutathera?

The financial trajectory for Lutathera is projected to be positive, driven by continued market expansion and potential label expansions.

Projected Market Growth

• Compound Annual Growth Rate (CAGR): Analysts project a steady CAGR in the low to mid-single digits for the GEP-NET treatment market, with Lutathera expected to capture a significant share.
• Drivers of Future Growth:
  • Increased Diagnosis: Enhanced awareness and diagnostic capabilities for GEP-NETs.
  • Geographic Expansion: Entry into new and emerging markets.
  • Pediatric Indications: Potential for expanded use in younger patient populations, pending regulatory approvals.
  • Combination Therapies: Exploration of Lutathera in combination with other agents to enhance efficacy.

Potential for Label Expansions

• Other Neuroendocrine Tumor Types: Research is ongoing to evaluate Lutathera's efficacy in other types of neuroendocrine tumors beyond GEP-NETs.
• Earlier Lines of Therapy: Clinical investigations into using Lutathera in earlier stages of GEP-NET treatment.
• Pediatric Use: Regulatory submissions for pediatric GEP-NETs are a key area of focus.

Impact of Generic Competition

• Patent Expiry: The patent protection for Lutathera will eventually expire, opening the door for generic or biosimilar competition.
• Therapeutic Equivalence: The complex nature of radiopharmaceuticals may present challenges for biosimilar development and regulatory approval compared to traditional small molecules.
• Market Share Erosion: Once generics enter, market share and pricing power will likely decrease.

Key Takeaways

Lutathera has secured a strong market position in the treatment of GEP-NETs, driven by its clinical efficacy and lack of direct competitors for its approved indication. Sales have reached approximately $570 million annually, with growth anticipated from increased diagnosis rates and geographic expansion. However, challenges include emerging competition from other radioligand therapies, manufacturing complexities, and the high cost of treatment. Future growth is contingent on continued market penetration, potential label expansions, and the eventual impact of generic competition following patent expiry.

Frequently Asked Questions

What is the primary indication for Lutathera?

Lutathera is indicated for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

What are the main clinical benefits of Lutathera demonstrated in trials?

Clinical trials, such as the NETTER-1 study, have shown that Lutathera significantly improves progression-free survival and overall survival compared to high-dose octreotide in patients with advanced GEP-NETs.

What are the key manufacturing challenges associated with Lutathera?

Manufacturing Lutathera involves complex radiopharmaceutical production, requiring specialized facilities, strict quality control, secure supply chains for radioactive isotopes, and meticulous cold chain management during distribution.

When is Lutathera's patent protection expected to expire?

Patent expiry timelines vary by region and specific patent. However, pharmaceutical patents typically last for a limited period, and companies often seek extensions. Investors should consult detailed patent databases for precise dates.

What are the most significant risks to Lutathera's future market performance?

The most significant risks include the emergence of competitive radioligand therapies, potential manufacturing or supply chain disruptions, challenges in maintaining favorable reimbursement for its high cost, and the eventual introduction of generic or biosimilar competitors after patent expiry.